Praxis Precision Medicines, Inc.
PRAX
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.8B
$351.81
▼ -0.94%
P/E
-27.21
Mkt Cap
$9.8B
52-Wk Range
$37.19–$392.70
52-Week Range
$37.19 - $392.70
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 763.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Differentiated mechanism of action using extrasynaptic-preferring GABAA modulators with improved safety profiles
- Strategic partnerships with leading biotech companies (Ionis, Purdue) and research institutions providing scientific validation and development support
- Precision medicine approach targeting genetically-defined epilepsy populations with high unmet medical needs and potential for accelerated regulatory pathways
Bear Case
1 risk
- High volatility (beta 2.8). Larger-than-normal price swings expected.
Growth
Stable outlook
Growing mid-cap in Biotechnology
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+38.5% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying PRAX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 6, 2026
Reported EPS of -$2.87 vs -$3.67 consensus (+21.8% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+21.8%
Revenue trend · last 8Q
—
—
-100%
-100%
-100%
-100%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$302.0K
$7.5M
$0
$0
$0
$0
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
11 analysts · 91% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
91%
Hold
0%
Sell
9%
Median Price Target
$575.00
▲ +63.4% vs $351.81
Latest: Goldman Sachs · Aug 21, 2026
1 analyst covering
vs Industry
How PRAX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related